Results 91 to 100 of about 8,428 (249)

Therapeutic potential of mesalamine-probiotic combination in enteric-coated tablet for modulating gut inflammation in IBD

Journal of Applied Pharmaceutical Research
Background: Mesalamine is widely used for inflammatory bowel disease (IBD) due to its local anti-inflammatory action, while probiotics help restore intestinal microbiota and modulate immune responses. Combining both may offer synergistic benefits for IBD
Pratiksha A. Thete, Milind P. Wagh, Vandana S. Nade   +2 more
doaj   +1 more source

Innovative Rectal Suspension of Mesalamine Utilizing Mesoporous Silica for Sustained and Colon-Specific Drug Delivery : Novel rectal suspension of mesalamine

Mesalamine is an anti-inflammatory drug for the treatment of ulcerative colitis-related colon cancer. The present study aims to evaluate the rectal suspension of mesoporous mesalamine for improved localized effect of the drug in the ulcerative colon of ...
Prajapati, Rajnish Umesh, Bicchali, Usha, Bhattacharyya, Sayani   +2 more
core   +1 more source

Similar pharmacokinetics of three dosing regimens comprising two oral delayed‐release mesalamine formulations in healthy adult volunteers: Randomised, open‐label, parallel‐group study [PDF]

, 2020
Niels Vande Casteele, Abhijeet Jakate, Brian McNamee, William J. Sandborn   +3 more
openalex   +1 more source

Induction of oxidative DNA damage by mesalamine in the presence of copper: A potential mechanism for mesalamine anticancer activity Induction of Oxidative DNA Damage by Mesalamine in the Presence of Copper: A Potential Mechanism for

, 2020
: Mesalamine is the first line pharmacologic intervention for patients with ulcerative colitis, and recent epidemiologic studies have demonstrated a protective association between therapeutic use of the drug and colorectal carcinoma.
Nathan Vandjelovic, Zhu H, Jianmin Wang, Vandjelovic N, Yunbo Li, Zimmerman Rp, Zhenquan Jia, Ryan P Zimmerman, Wang J Li, Y, Misra Hp, Hara P Misra, Hong Zhu, Jia Z   +13 more
core  

Mesalamine, but Not Sulfasalazine, Reduces the Risk of Colorectal Neoplasia in Patients with Inflammatory Bowel Disease [PDF]

, 2015
Anthony O’Connor, Christopher D. Packey, Mona Akbari, Alan C. Moss   +3 more
openalex   +1 more source

A rare case of mesalamine-induced eosinophilic pleural effusion

The Journal of Association of Chest Physicians
We present a very rare case of a 47-year-old man with a history of ulcerative colitis (UC), referred to as a case of an undiagnosed bilateral pleural effusion.
Ankit Bhatia, Sharad Joshi, Nitesh Tayal, Maj Gen Darshan Singh Bhakuni, Subhasish Majumdar   +4 more
doaj   +1 more source

Nephrotic syndrome after treatment of Crohn′s disease with mesalamine: Case report and literature review

Avicenna Journal of Medicine, 2012
Inflammatory bowel disease and its various treatments may affect the kidney in several ways. Recently, case reports have been published documenting the development of nephrotic syndrome after the treatment for inflammatory bowel disease with 5 ...
Belal M Firwana, Rim Hasan, Walid Chalhoub, Mazen Ferwana, Jin-Yong Kang, Joshua Aron, Joseph Lieber   +6 more
doaj   +1 more source

Formulation and Characterization of Mesalamine Pellets [PDF]

, 2019
The present work describes a study on “Formulation and Characterization of Mesalamine pellets” Mesalamine is an amino salicylate used for the treatment of inflammatory bowel disease including ulcerative colitis and crohn’s disease. Mesalamine diminishes
Anitha, G
core  

Development and Validation of HPLC Assay Method for Determination of Mesalamine in Bulk Drug and Tablet Formulation [PDF]

, 2014
Kuc B
openalex   +1 more source

Simple one-pot green method for large-scale production of mesalamine, an anti-inflammatory agent

Green Processing and Synthesis, 2019
We report a rapid and efficient synthesis protocol for mesalamine via a green approach with 2-chloro-5-nitrobenzoic acid as the starting material, for its large-scale production.
Vijaya Lakshmi C., Katari Naresh Kumar, Jonnalagadda Sreekantha B.   +2 more
doaj   +1 more source